Ertugliflozin vs. Glimepiride in Type 2 Diabetes Mellitus (T2DM) Participants on Metformin (MK-8835-002)
A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 1326 participants.
Also called NCT01999218
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; double masking; primary purpose treatment
- Phase
- Phase 3
- Enrolled
- 1,326 participants
- Sponsor
- Registry
-
NCT01999218 -
2013-003582-34
-
- Other papers using this trial's data
- Results of VERTIS SU extension study: safety and efficacy of ertugliflozin treatment over 104 weeks compared to glimepiride in patients with type 2 diabetes mellitus inadequately controlled on metformin
- Started
- (actual)
- Primary completion
- (actual)
- Completion
- (actual)
- Results first posted
- Countries
- Not reported
- Registry status
- Completed
Technical summary
Registry record NCT01999218. Randomized; double masking; primary purpose treatment. Start 2013-12-16 (actual); primary completion 2017-04-18 (actual). Results posted on 2018-05-11.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Ertugliflozin vs. Glimepiride in Type 2 Diabetes Mellitus (T2DM) Participants on Metformin (MK-8835-002)
- Condition
- Type 2 Diabetes Mellitus
- Intervention (Drug)
- Ertugliflozin 5 mg
- Intervention (Drug)
- Ertugliflozin 10 mg
- Intervention (Drug)
- Glimerpiride
- Intervention (Drug)
- Placebo to Ertugliflozin
- Intervention (Drug)
- Placebo to Glimepiride
- Intervention (Drug)
- Metformin
- Intervention (Drug)
- Sitagliptin
- Lead sponsor
- Merck Sharp & Dohme LLC
- Collaborator
- Pfizer
Record details
- Record id
cardio:ct-nct01999218- Content hash
b9f954266e9fa714f2d1d0fd93f952f11e93622b4865167e32e34ffcbe0cd4ed